Open AccessEffect of dipeptidyl peptidase 4 inhibitors on acute and subacute models of inflammation in male Wistar rats: An experimental study
Author(s) -
Urmila Anil Kagal,
Netravathi Basavaraj Angadi,
Somnath M. Matule
Publication year - 2017
Publication title -
international journal of applied and basic medical research/international journal of applied and basic medical research
Language(s) - English
Resource type - Journals
eISSN - 2248-9606
pISSN - 2229-516X
DOI - 10.4103/2229-516x.198516
Subject(s) - vildagliptin , saxagliptin , medicine , inflammation , dipeptidyl peptidase 4 , diabetes mellitus , type 2 diabetes , pharmacology , type 2 diabetes mellitus , dipeptidyl peptidase , endocrinology , sitagliptin , enzyme , biochemistry , chemistry
The prevalence of Type 2 diabetes mellitus (T2DM) has reached alarming proportions due to the rapidly increasing rates of this disease worldwide. Preclinical and clinical studies have revealed elevated levels of inflammatory markers in a vast number of illnesses such as T2DM, obesity, and atherothrombosis collectively called metabolic syndrome leading to adverse cardiovascular events. Dipeptidyl peptidase 4 (DPP-4) inhibitors which are the enhancers of glucagon-like peptide 1 (GLP -1), could have anti-inflammatory potential which could help in reducing cardiovascular complications of diabetes and benefit patients suffering from the metabolic syndrome.